Background: Castration-resistant prostate cancer (CRPC) represents a therapeutic challenge for current medications.
Integrative genomic, transcriptomic, and RNAi analysis indicates a potential oncogenic role for FAM110B in castration-resistant prostate cancer.
Sex, Specimen part, Disease, Disease stage, Cell line, Treatment, Race
View Samples